Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. reports on Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with... in Science & Health.
Take A Coffee NEWS Staff··2 min read
Arrowhead Pharmaceuticals, Inc. reported Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS). Take A Coffee NEWS is tracking the story on the Science & Health desk for readers following medicine, public health, research, climate, space, and science policy.
Source
Arrowhead Pharmaceuticals, Inc.
Why it matters
The story belongs in this desk because it may affect readers tracking medicine, public health, research, climate, space, and science policy.